LB1 - Late Breaker - 1: LGV, chlamydia and mpox

Moderator(s)

• 

  Nicola Low, MD (she/her/hers)

  Professor of Epidemiology and Public Health
  University of Bern
  Bern, Bern, Switzerland
• 

  Kate Seib, BSc (Hons), PhD (she/her/hers)

  Professor, Associate Director (Research)
  Institute for Glycomics, Griffith University, Queensland, Australia

Presentations:

• 14:30 – 14:45 CST

  Prevalence and epidemiology of Lymphogranuloma venereum in France, 2020-2022
  

  Primary Presenter: Cecile Bebear, MD PhD (she/her/hers) – Bordeaux University Hospital
• 14:45 – 15:00 CST

  Genetic diversity of Chlamydia trachomatis infection among patients presenting with genital lesions in Malawi
  

  Primary Presenter: Christopher M. Hennelly, n/a – Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
• 15:00 – 15:15 CST

  Evaluating immunological responses of mRNA-based Chlamydia vaccines
  

  Primary Presenter: Wei He, n/a – Lawrence Livermore National Laboratory
• 15:15 – 15:30 CST

  Mpox resurgence in 2023 in Toronto, Canada – surveillance and vaccine approaches
  

  Primary Presenter: Sylvia Ota, MHSc (she/her/hers) – Toronto Public Health

  Co-Author: Rita Shahin, n/a – Toronto Public Health
• 15:30 – 15:45 CST

  Modelling the impact of vaccination and sexual behavior adaptation on reported cases of mpox in Washington D.C.
  

  Primary Presenter: Patrick A. Clay, PhD (he/him/his) – Centers for Disease Control and Prevention
• 15:45 – 16:00 CST

  Modeling potential mpox resurgence among gay, bisexual, and other men who have sex with men in Washington, DC.
  

  Primary Presenter: Emily D. Pollock, PhD (she/her/hers) – Centers for Disease Control & Prevention